I thought the earnings were pretty decent. Obviously the market disagrees but I would love to hear your opinions of the earnings and today’s consequent drop in price.
02:35 AM EST, 02/10/2026 (MT Newswires) -- GSK (GSK.L) said China's Center for Drug Evaluation accepted for review its application for Arexvy as a vaccine in adults against respiratory syncytial virus-caused lower respiratory tract disease. According to a Tuesday filing, the British drugmaker is seeking approval in China for the use of the vaccine in adults aged at least 60 years. It supported the application with positive data from a phase 3 trial, and a regulatory decision is expected in 2027.
I thought the results today were decent, nice dividend growth for the upcoming and next year as well as the share buybacks. Market seems happy with the results what do you all think?
News on a new purchase for $GSK to strengthen its position in respiratory, immunology & inflammation offerings.
https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-buy-rapt-therapeutics-22-billion-2026-01-20/
GSK Q3 2025 Earnings in 5 Days: Execution vs. FX & IRA headwinds
When: Wed 29 Oct 2025, 07:00 GMT; management presentation follows (webcast link on GSK IR).
Street sees steady quarter with specialty meds leading; focus on whether FY25 stays “top-end” of guidance as FX and US policy headwinds bite.
4 Key Takeaways
• Consensus (Q3’25E): Turnover £8.24bn, Core EPS ~47.1p, Op. margin ~32.4%; WANS ~4,036m (buybacks reduce share count).
• FY25 Guidance (CER): Sales +3–5%, Core OP +6–8%, Core EPS +6–8%, management guiding toward the top end.
• Returns: FY25 dividend run-rate ~64p indicated earlier; £2bn buyback programme underway (three tranches completed/underway YTD).
• Watchpoints (Q3): FX −1% to −2% drag on sales; US IRA Part D redesign ~£400–500m FY headwind; step-up in SG&A to support launches; vaccine mix (Shingrix/Arexvy seasonality) and oncology momentum (Jemperli/Ojjaara).
⭐ Star Rating
• Dividend Strength: ⭐⭐⭐⭐☆
• Financial Health: ⭐⭐⭐⭐☆
• Growth/Pipeline: ⭐⭐⭐☆☆
• Valuation: ⭐⭐⭐☆☆
• Management/Execution: ⭐⭐⭐⭐☆
Overall: ⭐⭐⭐⭐☆ (4/5) Solid execution and shareholder returns; mind FX/IRA and vaccine mix into Q4.
If specialty meds + oncology keep comping strong and FX/IRA headwinds are contained, GSK can hold the top-end FY25 guide. I’ll be watching EPS leverage vs. SG&A step-up and any colour on Arexvy/Shingrix trajectory into Q4.
ccc1990
преди 8 месеца
Lovely stuff
ContrarianCNT
преди 8 месеца
What's happening guys?
Unable to check what's going on. Biggest daily pop I can remember on GSK.
На тази страница може да видиш съдържание, генерирано от клиентите, за което Trading 212 не носи отговорност. Винаги прави собствени проучвания. Trading 212 предоставя единствено услуга за изпълнение и не предлага инвестиционен съвет или управление на портфолиото.
Инвестирай в готови пайове или създай свой собствен, като избираш от хиляди акции и ETF-и
Научи повече
Научи повече
Гледай видеото
Така можеш да притежаваш дял дори от най-скъпите акции като Google, Amazon и Apple
Гледай видеото
Euronext Paris
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
London Stock Exchange
Euronext Lisbon
Euronext Paris
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
London Stock Exchange
Euronext Lisbon
Виж всички инструменти за търговия
Поддръжка 24/7
Отговаряме в чата средно за 29 секунди
Започни да търгуваш сега
Присъедини се към над 5 милиона потребители
Изтегли приложението
Отвори сметка
Инсталирай мобилното приложение
Стойностите са глобални. Броят клиенти включва само тези със захранени сметки.
Отлично
Оценка 4,6/5 въз основа на 93 567 отзива в
Trustpilot
Оценка 4,6/5 въз основа на 93 567 отзива в
Trustpilot
Поканен
Great
Immediate updates, easy to use and manage.
Поканен
Very easy to use
Very easy to use. Intuitive app and makes it straight forward to sit back and let your investment's do its work
Поканен
Ease of use
Easy to set up an account
Easy to transfer funds
Great interest rate
Great all round experience
Поканен
Easy to set up my account
Easy to set up my account easy to access balance and a very good rate in interest.
Поканен
easy to use platform
easy to use platform, love the ability to transfer cash isa funds into stocks and shares isa
Поканен
Simple and Informative platform
I wanted a platform which was offering great rates for my ISA, but discovered not only did this platform do that. It also gave me an insight into trading and world markets. It's quite simply brilliant.
Поканен
Great app that provides all my account…
Great app that provides all my account info at my fingertips
Поканен
Easy to use.
Easy to use.
Can view everything simply.
Just what I need.
Поканен
Good interest rate and can take the…
Good interest rate and can take the money out whenever I want.
Поканен
So easy
So easy! Makes investing a pleasure
Поканен
I’m novice and useless with technology…
I’m novice and useless with technology but I found this an easy site to navigate and to deal with.
Поканен
Nice app
Great app, very intuitive and simple to use. Gold standard.
Поканен
Very easy to use
Very easy to use. Very clear. And a joy to watch my savings rise
Поканен
Easy to use
Functional and easy to use and track my cash & stocks & shares isas
Поканен
Easy access to my account and how Easy…
Easy access to my account and how Easy it is to navigate the212 application.
Поканен
Simple and easy to use app
Simple and easy to use app. Ease of setting up recurring payments. Great for a beginner that has no prior knowledge or experience of investing.
Поканен
Easy and simple app
Easy and simple app, tells you daily your interest which I like and I get emails. The updating is really good.
Поканен
Very easy and highly recommend
Very easy and highly recommend. Straight forward to use and cost instructions on the fees and charges.
Поканен
Great way for your money to build
Just very pleased with the level of savings rate and steady build up.
Поканен
Cool app
User friendly mobile app that makes investing easy and funny. Fast navigation throughout the app. In a few clicks can see basically every information one might require.
Някои от положителните клиентски отзиви
Нашите награди
Често задавани въпроси
Каква е цената на акциите на GSK (GSK)?
Текущата цена на GSK (GSK) е 1901,3 GBX.
Какъв е 52-седмичният максимум на GSK?
52-седмичният максимум за GSK е 2281,7 GBX.
Какъв е 52-седмичният минимум на GSK?
52-седмичният минимум за GSK е 1318,7 GBX.
Каква е седмичната ефективност на GSK?
През изминалата седмица цената на GSK се е променила с -0,87%.
Какво е месечната ефективност на GSK?
През изминалия месец цената на GSK се е променила с 0,02%.
Каква е 3-месечната ефективност на GSK?
През последните три месеца цената на GSK се е променила с -10,4%.
Каква е 6-месечната ефективност на GSK?
През последните шест месеца цената на GSK се е променила с 3,73%.
Каква е годишната ефективност на GSK?
През изминалата година цената на GSK се е променила с 28,03%.